Clinical trials: CD40L-HyperIgM Syndrome
Immunoproliferative Disorder
Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome
The primary goal of this Phase I/II study is to assess the immune response and safety of recombinant human CD40 ligand (rhuCD40L) in patients with X-linked hyper IgM syndrome (XHIM).
- Trial name
- NCT00001145
- Testing
- Bacteriophage, rhuCD40L, KLH
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)